London-based market intelligence agency, Aging Analytics Agency, in a profile of over 2,800 companies, 1,500 investors and 80 R&D hubs, found that undiagnosed diabetes cases had reached 40 percent with the highest incidences in Africa, Southeast Asia and Western Pacific.
In a press statement, AAA said only half of the diagnosed diabetes patients have access to licensed care despite advances in technology in managing the disease.
AAA is focused on longevity analysis and is a subsidiary of Deep Knowledge Group that now includes cutting-edge Diabetes Global Industry IT platform and dashboard.
According to AAA, diabetes technology is rapidly improving and can be beneficial for all those living with diabetes. While many diabetes sufferers use self-monitoring of blood glucose and insulin injections or insulin pens, these tools are being replaced by more advanced technologies that provide more useful data and greater convenience.
Advanced tools such as continuous glucose monitors (CGMs) provide real-time data to help people with diabetes to avoid experiencing low and high blood sugar levels.
Access to healthcare
AAA’s data are based on scientific and clinical evidence and can be used by healthcare professionals, R&D professionals, and investors in the diabetes marketAccording to the data, undiagnosed diabetes cases have reached about 40 percent globally, with developed regions exhibiting similar levels.
It said the most concerning statistics are seen in Africa, where 60 percent of diabetes cases go undiagnosed, followed by South-East Asia at 57 percent, and the Western Pacific Region at 56 percent.
Despite the prevalence of diagnosed cases, the Diabetes Global Industry Overview 2023 reveals that only 50 percent of individuals with diabetes have access to licensed healthcare services.
This stark disparity highlights the pressing need to improve access to diabetic care on a global scale.
The report offers diabetes market analysis and insights into the use of advanced technology in the management of persons with diabetes.
Active clinical trials
Housed within AAA’s Global Diabetes IT-Platform, the report said over half of global diabetes industry investors (approximately 52 percent) are based in the United States, totalling 746 investors. The United Kingdom and China follow, with around 10 percent each (76 and 71 investors, respectively).
More than 2,100 active clinical trials are ongoing worldwide, with North America serving as the primary hub, hosting over 53 percent of clinical trial sponsors. More than 530 companies specialize in diabetes diagnostics, with the USA leading the market, housing over 65 percent of these companies.
The US boasts 1,466 medical centers specializing in diabetes treatment, representing approximately 78 percent of the global total. The majority of research and development centers dedicated to diabetes research are located in the USA, comprising 81 percent of all analyzed centers.
Australia follows at 5 percent, and the United Kingdom and India each account for 2 percent, with the remaining 9 percent distributed across seven countries.
A growing crisis
AAA’s report highlights that glucose level control remains the primary strategy for diabetes management, with human insulin being the most commonly used drug. Advanced insulin therapy and non-insulin medications are prevalent in the US, Canada, China, India, and Brazil.
The pharmaceutical market for diabetes is divided into three subsectors: Therapeutics (38.7 percent), Drug Delivery (32.3 percent), and Devices (24.7 percent).
The diabetes market is fiercely competitive, with traditional insulin dominating approximately half of the market. GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors are emerging as significant players, collectively comprising 44 percent of the market. Notably, Novo Nordisk, Sanofi, Eli Lilly, and Merck together account for approximately 72 percent of the global diabetes market.
The comprehensive report provides a vital overview of the global diabetes landscape, highlighting the urgent need for improved access to diabetes care and innovative solutions to address the growing crisis.
#UndiagnosedDiabetes #Diabetes #AgingAnalyticsAgency #Healthcare #ClinicalTrials #AGrowingCrisis #Health #MedicalHealth #OpinYon #WeTakeAStand